Current Peptide and Protein Candidates Challenging HIV Therapy beyond the Vaccine Era

Koollawat Chupradit , Sutpirat Moonmuang , Sawitree Nangola , Kuntida Kitidee , Umpa Yasamut , Marylène Mougel (1) , Chatchai Tayapiwatana

1 IRIM - Institut de Recherche en Infectiologie de Montpellier

Human immunodeficiency virus (HIV) is a causative agent of acquired immune deficiency syndrome (AIDS). Highly active antiretroviral therapy (HAART) can slow down the replication of HIV-1, leading to an improvement in the survival of HIV-1-infected patients. However, drug toxicities and poor drug administration has led to the emergence of a drug-resistant strain. HIV-1 immunotherapy has been continuously developed, but antibody therapy and HIV vaccines take time to improve its efficiency and have limitations. HIV-1-specific chimeric antigen receptor (CAR)-based immunotherapy founded on neutralizing antibodies is now being developed. In HIV-1 therapy, anti-HIV chimeric antigen receptors showed promising data in the suppression of HIV-1 replication; however, autologous transfusion is still a problem. This has led to the development of effective peptides and proteins for an alternative HIV-1 treatment. In this paper, we provide a comprehensive review of potent anti-HIV-1 peptides and proteins that reveal promising therapeutic activities. The inhibitory mechanisms of each therapeutic molecule in the different stages of the HIV-1 life cycle will be discussed herein.

Domaines: Médecine humaine et pathologie; Immunologie; Microbiologie et Parasitologie

Koollawat Chupradit, Sutpirat Moonmuang, Sawitree Nangola, Kuntida Kitidee, Umpa Yasamut, et al.. Current Peptide and Protein Candidates Challenging HIV Therapy beyond the Vaccine Era. Viruses, 2017, 9 (10), pp.281. ⟨10.3390/v9100281⟩. ⟨hal-02141193⟩